

FIGURE 1




Treatment	% Inhibition (Day 16)	p-value
Compound 1 vs. Compound 1 + Docetaxel	75	0.01
Docetaxel vs. Compound 1 + Docetaxel	82	< 0.0001

FIGURE 2



Treatment	% Inhibition (Day 20)	p-value
Cmpd 1 vs. Cmpd 1 + Docetaxel	78	0.01
Docetaxel vs. Cmpd 1 + Docetaxel	62	0.04

FIGURE 3



Treatment	% Inhibition (Day 57)	p-value
Docetaxel vs. Compound 1 + Docetaxel	82	0.008

FIGURE 4




CMC PO & 7.5% ET in D5W IV
Compound 1 40 mg/kg/day PO
Docetaxel 5 mg/kg Once /wk x 3
Docetaxel 10 mg/kg Once /wk x 3
Docetaxel 15 mg/kg Once /wk x 3
Compound 1 40 mg/kg/day + Docetaxel 5 mg/kg
Compound 1 40 mg/kg/day + Docetaxel 10 mg/kg
Compound 1 40 mg/kg/day + Docetaxel 15 mg/kg
Average Tumor Volume (mm3)
1500
1000
500
0
1 6 11 16 21 26 31 36 41 46 51 56 61 66 71 76 81
Days Post Implantation

FIGURE 5



Treatment	% Inhibition	p-value
Cmpd 1 vs. Cmpd 1 + 5 -FU	78%	0.006
5-FU vs. Cmpd 1 + 5 -FU	76%	0.01

FIGURE 6




CMC Vehicle Control
Saline Vehicle Control
Cmpd 1 40 mg/kg/day
Doxorubicin 4 mg/kg IV QOD
Compound 1 40 mg/kg/day + Doxorubicin 4 mg/kg QOD
Average Tumor Volume (mm3)
1000
500
0
1
6
11
16
21
26
31
36
Days Post Implantation


FIGURE 7



Tumor Growth Delay of Combination vs:	Days Delay	p-value
Compound 1	30	0.0005
Cisplatin	23	0.0009

NCI-H526 cells inoculated sc into athymic mice (n=10/group). When tumors were ~ 250mm^3, oral dosing of Compound 1 at 40 mg/kg/day, STI-571 at 160 mg/kg/BID or vehicle control was initiated.

Figure 8


Vehicle PO
Compound 1 20 mg/kg/day PO
Compound 1 40 mg/kg/day PO
CPT-11 100mpk (IP, Qwkx3)
Compound 1 20mg/kg/day + CPT-11 100 mg/kg qwk x 3
Compound 1 40 mg/kg/day + CPT-11 100 mg/kg qwk x 3
Average Tumor Volume (mm3)
2000
1500
1000
500
0
1
6
11
16
21
26
31
36
41
46
51
56
Days Post Implantation